Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Transl Psychiatry ; 5: e674, 2015 Nov 03.
Article in English | MEDLINE | ID: mdl-26529427

ABSTRACT

Chronic ventromedial prefrontal cortex (vmPFC) deep brain stimulation (DBS) improves depressive-like behaviour in rats via serotonergic and neurotrophic-related mechanisms. We hypothesise that, in addition to these substrates, DBS-induced increases in hippocampal neurogenesis may also be involved. Our results show that stress-induced behavioural deficits in the sucrose preference test, forced swim test, novelty-suppressed feeding test (NSFT) and elevated plus maze were countered by chronic vmPFC DBS. In addition, stressed rats receiving stimulation had significant increases in hippocampal neurogenesis, PFC and hippocampal brain-derived neurotrophic factor levels. To block neurogenesis, stressed animals given DBS were injected with temozolomide. Such treatment reversed the anxiolytic-like effect of stimulation in the NSFT without significantly affecting performance in other behavioural tests. Taken together, our findings suggest that neuroplastic changes, including neurogenesis, may be involved in specific anxiolytic effects of DBS without affecting its general antidepressant-like response.


Subject(s)
Behavior, Animal/physiology , Deep Brain Stimulation , Neuronal Plasticity/physiology , Stress, Psychological/physiopathology , Stress, Psychological/therapy , Animals , Disease Models, Animal , Male , Neurogenesis/physiology , Rats , Rats, Inbred F344
2.
Proc Natl Acad Sci U S A ; 102(51): 18620-5, 2005 Dec 20.
Article in English | MEDLINE | ID: mdl-16352709

ABSTRACT

Although anecdotal reports suggest that cannabis may be used to alleviate symptoms of depression, the psychotropic effects and abuse liability of this drug prevent its therapeutic application. The active constituent of cannabis, delta9-tetrahydrocannabinol, acts by binding to brain CB1 cannabinoid receptors, but an alternative approach might be to develop agents that amplify the actions of endogenous cannabinoids by blocking their deactivation. Here, we show that URB597, a selective inhibitor of the enzyme fatty-acid amide hydrolase, which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide, exerts potent antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test. Moreover, URB597 increases firing activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in the nucleus locus ceruleus. These actions are prevented by the CB1 antagonist rimonabant, are accompanied by increased brain anandamide levels, and are maintained upon repeated URB597 administration. Unlike direct CB1 agonists, URB597 does not exert rewarding effects in the conditioned place preference test or produce generalization to the discriminative effects of delta9-tetrahydrocannabinol in rats. The findings support a role for anandamide in mood regulation and point to fatty-acid amide hydrolase as a previously uncharacterized target for antidepressant drugs.


Subject(s)
Antidepressive Agents/pharmacology , Arachidonic Acids/metabolism , Benzamides/pharmacology , Brain/drug effects , Brain/metabolism , Carbamates/pharmacology , Norepinephrine/metabolism , Serotonin/metabolism , Animals , Behavior, Animal/drug effects , Cannabinoid Receptor Agonists , Dronabinol/pharmacology , Endocannabinoids , Hydrolysis/drug effects , Male , Mice , Mice, Inbred C57BL , Neurons/drug effects , Neurons/metabolism , Polyunsaturated Alkamides , Rats , Receptors, Cannabinoid/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...